Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
Isa F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, Olenchock BA, Brackin T, Ganguly S, Forleo-Neto E, Faria L, Heirman I, Marovich M, Hutter J, Polakowski L, Irvin SC, Thakur M, Hooper AT, Baum A, Petro CD, Fakih FA, McElrath MJ, De Rosa SC, Cohen KW, Williams LD, Hellman CA, Odeh AJ, Patel AH, Tomaras GD, Geba GP, Kyratsous CA, Musser B, Yancopoulos GD, Herman GA; Trial Working Group. Isa F, et al. Among authors: hooper at. Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00421-3. doi: 10.1016/S1473-3099(24)00421-3. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39236733
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. Among authors: hooper at. medRxiv [Preprint]. 2021 Sep 18:2021.06.14.21258569. doi: 10.1101/2021.06.14.21258569. medRxiv. 2021. Update in: JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939 PMID: 34159343 Free PMC article. Updated. Preprint.
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. O'Brien MP, et al. Among authors: hooper at. medRxiv [Preprint]. 2021 Jun 17:2021.06.14.21258567. doi: 10.1101/2021.06.14.21258567. medRxiv. 2021. Update in: N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682 PMID: 34159344 Free PMC article. Updated. Preprint.
Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19.
Wang B, Golubov J, Oswald EM, Poon P, Wei Q, Lett C, Shehadeh F, Kaczynski M, Felix LO, Mishra B, Mylona EK, Wipperman MF, Chio E, Hamon SC, Hooper AT, Somersan-Karakaya S, Musser BJ, Petro CD, Hamilton JD, Sleeman MA, Kalliolias GD, Mylonakis E, Skokos D. Wang B, et al. Among authors: hooper at. EBioMedicine. 2024 Oct;108:105334. doi: 10.1016/j.ebiom.2024.105334. Epub 2024 Sep 12. EBioMedicine. 2024. PMID: 39270622 Free PMC article.
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.
Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, Xiao J, Turner KC, Davis JD, Irvin SC, Pan C, Atmodjo D, Hooper AT, Hamilton JD, Hussein M, Subramaniam D, Roque-Guerrero L, Kohli A, Mylonakis E, Geba GP, Cox E, Braunstein N, Dakin P, Kowal B, Bhore R, DiCioccio AT, Hughes D, Herman GA; Trial Investigators. Norton TD, et al. Among authors: hooper at. J Pediatric Infect Dis Soc. 2024 Nov 27;13(11):589-593. doi: 10.1093/jpids/piae105. J Pediatric Infect Dis Soc. 2024. PMID: 39351798 Free PMC article. Clinical Trial.
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study.
Norton TD, Thakur M, Ganguly S, Ali S, Chao J, Waldron A, Xiao J, Patel Y, Turner KC, Davis JD, Irvin SC, Pan C, Atmodjo-Watkins D, Hooper AT, Hamilton JD, Subramaniam D, Bocchini JA, Kowal B, DiCioccio AT, Bhore R, Geba GP, Cox E, Braunstein N, Dakin P, Herman GA. Norton TD, et al. Among authors: hooper at. BMJ Open. 2024 Oct 8;14(10):e087431. doi: 10.1136/bmjopen-2024-087431. BMJ Open. 2024. PMID: 39384241 Free PMC article. Clinical Trial.
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.
Sindher SB, Nadeau KC, Chinthrajah RS, Leflein JG, Bégin P, Ohayon JA, Ponda P, Wambre E, Liu J, Khokhar FA, Akinlade B, Maloney J, Orengo JM, Hamilton JD, Kamal MA, Hooper AT, Patel N, Patel K, Laws E, Mannent LP, Radin AR. Sindher SB, et al. Among authors: hooper at. Allergy. 2024 Dec 14. doi: 10.1111/all.16404. Online ahead of print. Allergy. 2024. PMID: 39673452
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.
Chinthrajah RS, Sindher SB, Nadeau KC, Leflein JG, Spergel JM, Petroni DH, Jones SM, Casale TB, Wang J, Carr WW, Shreffler WG, Wood RA, Wambre E, Liu J, Akinlade B, Atanasio A, Orengo JM, Hamilton JD, Kamal MA, Hooper AT, Patel K, Laws E, Mannent LP, Adelman DC, Ratnayake A, Radin AR. Chinthrajah RS, et al. Among authors: hooper at. Allergy. 2024 Dec 14. doi: 10.1111/all.16420. Online ahead of print. Allergy. 2024. PMID: 39673367
Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection.
Petro CD, Hooper AT, Peace A, Mohammadi K, Eagan W, Elbashir SM, DiPiazza A, Makrinos D, Pascal K, Bandawane P, Durand M, Basu R, Coppi A, Wang B, Golubov J, Asrat S, Ganguly S, Koehler-Stec EM, Wipperman MF, Ehrlich G, Gonzalez Ortiz AM, Isa F, Lewis MG, Andersen H, Musser BJ, Torres M, Lee WY, Edwards D, Skokos D, Orengo J, Sleeman M, Norton T, O'Brien M, Forleo-Neto E, Herman GA, Hamilton JD, Murphy AJ, Kyratsous CA, Baum A. Petro CD, et al. Among authors: hooper at. Sci Transl Med. 2024 Nov 6;16(772):eadn0396. doi: 10.1126/scitranslmed.adn0396. Epub 2024 Nov 6. Sci Transl Med. 2024. PMID: 39504352
60 results